Short answer · Medically reviewed summary · Last updated: 2023-07-13
Adult Polyglucosan Body Disease (APBD) is a rare genetic disorder that affects the nervous system. It is characterized by the accumulation of abnormal glycogen deposits in nerve cells, leading to progressive neurological symptoms.
What is the prevalence of Adult Polyglucosan Body Disease (APBD)?
Prevalence of Adult Polyglucosan Body Disease (APBD): how many people are affected worldwide, differences by sex and region, with sources.
Adult Polyglucosan Body Disease (APBD) is a rare genetic disorder that affects the nervous system. It is characterized by the accumulation of abnormal glycogen deposits in nerve cells, leading to progressive neurological symptoms. APBD is inherited in an autosomal recessive manner, meaning that both parents must carry a mutated gene for their child to be affected.
The exact prevalence of APBD is not well-established due to its rarity and underdiagnosis. However, it is estimated to affect approximately 1 in 100,000 to 1 in 1,000,000 individuals worldwide. The disease primarily affects adults, typically appearing between the ages of 40 and 60, although cases in younger individuals have been reported.
APBD is more commonly found in individuals of Ashkenazi Jewish descent, with a higher carrier frequency in this population. Genetic testing can help identify carriers and individuals at risk of developing the disease.
Early diagnosis and management of APBD are crucial for optimizing patient outcomes. While there is currently no cure for APBD, symptomatic treatments and supportive care can help alleviate some of the neurological symptoms and improve quality of life.
